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Background
In recent years, the use of disposables in the pharma-
ceutical industry has increased extensively. Disposables
can be used in many areas of biopharmaceutical produc-
tion. The use of disposables not only reduces investment
costs, but also requires less manpower to operate, since
time consuming change-over procedures are signifi-
cantly reduced. In addition, disposables enable a high
flexibility by reducing unit operation times such as
cleaning and sterilization as well as the validation of
these procedures [1]. Disposable bioreactors can be sub-
divided into two main groups, static and dynamic sys-
tems. The dynamic systems differ with regard to the
power input in stirred, vibromixed or wave-induced sys-
tems [2]. Since the power input, the mixing time, the tip
speed and the oxygen transfer coefficient may influence
the cell culture process and the product quality itself, a
thorough characterization of the system used is neces-
sary [3]. SSB (stainless steel bioreactors) and SUB (single
use bioreactors) differ in terms of their physical design.
Usually, an SSB is equipped with two or three stirrer
blades. In contrast, stirred SUBs usually have just one
stirrer blade. In addition, the design and the position of
the stirrer differ significantly. These distinctions lead to
different physical characteristics regarding the power
input, mixing time, and tip speed. The SUBs are charac-
terized by a significantly lower power input and tip
speed and a significantly higher mixing time. In order to
maintain a sufficient oxygen transfer coefficient, the sin-
gle use bioreactor is equipped with a micro sparger with
a pore size of 25 µm. Furthermore, pure oxygen can be
used to achieve higher dissolved oxygen concentrations
in the cell cultivation medium. This study describes the
influence of these technical differences on the perfor-
mance of a CHO cell line and the product quality of a
monoclonal antibody.
Results
After inoculation, the cells were cultured in both sys-
tems in a fed batch mode with two continuous feeds for
twelve days. Figure 1a shows the viable cell density as a
function of time. Whereas the overall growth character-
istic of the cells in both systems are comparable over
the whole cultivation time, from 92 h until 188 h, the
cells in the SSB are characterized by a significantly (*)
faster growth (p< 0.05). The viability of the cells in both
systems remains between 90 % and 100 % over the
whole cultivation time (data not shown). Figure 1b
shows the LDH activity in both systems as a function of
time as an indicator of cell lysis. Up to 68 h cultivation
time the LDH activity in both systems is comparable.
Thereafter, the LDH activity measured in the SUB is sig-
nificantly (*) higher in comparison to the SSB (p < 0.05).
Figure 1c shows the product titer [%] produced by the
cells in the SSB in comparison to the SUB and Figure
1d shows the specific productivity. Between 140 h and
250 h the product titer in the SSB is slightly higher in
comparison to the SUB, whereas the titer at harvest is
comparable. Since the growth of the cells in the SSB is
faster in comparison to the cells in the SUB, the specific
productivity of the cells cultivated in the SUB is higher.
Figure 1d shows the IEC data of the antibody produced
by the CHO cells in the SUB and the SSB. Whereas the
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higher in comparison to the antibody of the SUB the
difference is not significant. The main peaks are com-
p a r a b l e .T h eb a s i cr e g i o no ft h ea n t i b o d yo ft h eS S Bi s
slightly lower in comparison to the SUB, balancing the
slight increase in acidic region observed for the antibody
derived from the SSB.
The SEC patterns of both products are almost identi-
cal (Tab. 1). The glycopatterns of the mAB produced in
the SUB and of the mAB produced in the SSB shows no
significant differences (Fig. 1e). The G0 fraction of the
mAB produced in the SSB is slightly higher in compari-
son to the G0 fraction of the mAB produced in the SUB
whereas the G1 fraction of the mAB produced in the
SSB is slightly lower compared the mAB produced in
the SUB. The G2 fraction is very similar. The G0-Fucose
value of the mAB produced in the SSB is higher than
for mAB produced in the SUB, which leads to a higher
overall a-fucose value for the SSB derived product com-
pared to the SUB derived product. However, all these
differences are not significant. All other fractions are
comparable between both antibodies. To investigate the
influence of both bioreactor types on the impurity pro-
file, the DNA and HCP values of the harvested superna-
tant were compared. Figure 1f shows the specific DNA
concentration (DNA concentration divided by viable cell
density) of the harvested supernatant of the SSB and the
SUB. The specific DNA concentration of the harvested
Figure 1a Viable cell density
Figure 1b LDH activity
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the SUB. However, theses differences are not significant.
Figure 1g shows the specific HCP concentration mea-
sured in the harvested supernatant of the SSB and the
SUB. The specific HCP concentration (HCP concentra-
tion divided by viable cell density) of the SUB is slightly
higher compared to the specific HCP concentration of
the SSB. Again, these differences are not significant.
Conclusions
The present study describes the influence of a single use
bioreactor on the performance of a production CHO
cell line, on the product quality of the produced anti-
body and the process related impurities in comparison
to a commercial stainless steel bioreactor. It seems that
the microsparger of the SUB lead to a cell damage,
which is measured by LDH activity. Nevertheless, our
findings indicate that this cell damage has no influence
Table 1 SEC pattern
Bioreactor-type Monomer
[%]
HMW
[%]
LMW
[%]
SSB 99.7 ± 0 0.267 ± 0.047 0.1 ± 0
SUB 99.7 ± 0 0.3 ± 0 0.1 ± 0
Figure 1c Product titer
Figure 1d IEC pattern
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Figure 1f DNA concentration
Figure 1g HCP concentration
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Page 4 of 5on the productivity, the concentration of DNA and HCP
and, most importantly on the quality of the antibody.
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